Innate Pharma SA, of Marseille, France, said it intends to issue and sell, subject to market and other conditions, about 10.7 million of its ordinary shares in a global offering to specified categories of investors, comprised of an initial public offering of American depositary shares (ADSs), each representing one ordinary share, in the U.S., and a concurrent private placement of ordinary shares in Europe and other countries outside the U.S.